Volume 94, supplement 3, numéro spécial, juin 2007

Éditorial

Actualités sur la gemcitabine et le pemetrexed (p.83)
Jean-Philippe Spano, Jacques-Olivier Bay

Synthèse

Gemcitabine: from preclinic to clinic passing by pharmacokinetics (p.85-9)
François Lokiec, Amélie Lansiaux

Updates on gemcitabine on metastatic breast cancer (p.90-4)
Joseph Gligorov, Fréderic Selle, Ahmed Khalil, Faddi Abbas, Moïse Namer, Jean-Pierre Lotz

Gemcitabine and non small-cell lung cancer (p.95-103)
Stéphane Vignot, Benjamin Besse

Gemcitabine and digestive carcinomas (p.104-15)
Pierre Blanchard, Florence Huguet, Thierry André

Gemcitabine and pemetrexed in genito-urinary tumors treatment (p.116-21)
Aude Fléchon

Docetaxel and gemcitabine combination in soft-tissue sarcomas treatment (p.122-6)
Jacques-Olivier Bay, Aurélie Cabrespine, Olivier Gilliot, Corine Bailly, Catherine Vincent, Florence Mishellany, Pierre Gimbergues

Gemcitabine and radiotherapy in non-small cell lung cancer : dolce vita at last ! (p.127-33)
Nicolas Girard, Françoise Mornex

Pemetrexed: from preclinic to clinic (p.134-8)
Amélie Lansiaux, François Lokiec

Update of pemetrexed in thoracic oncology (p.139-41)
Jeanne-Marie Brechot, Jean-François Morère

Pemetrexed development in oncology (p.142-8)
Loïc Chaigneau, Christian Villanueva, Antoine Thierry-Vuillemin, Christine Legat-Fagnoni, Thierry N’Guyen, Tristan Maurina, Véronique Lorgis, Xavier Pivot

Gemcitabine and pemetrexed: novel associations and mechanisms of resistance (p.149-54)
Marie-Paule Sablin, Christophe Le Tourneau, Ghassan El Maalouf, Eric Raymond, Sandrine Faivre